Lilly’s rheumatoid arthritis drug cuts COVID-19 deaths in trial, data shows

Lilly said the effect was most pronounced in patients on oxygen therapy, according to data from a U.S. government-backed trial, which however, was not designed to measure the effectiveness of baricitinib in preventing death. In-line with data disclosed in September, the combination helped shorten the median recovery time by one day compared to remdesivir, meeting the study’s main goal. Lilly said 5.1% of patients on the drug combination died after 29 days versus 7.8% patients given remdesivir, which is already authorized in the U.S. for treating COVID-19 patients, and a placebo.

Source: yahoo.com/news